Vimarsana
Biggest News Aggregation in the World

Nuno Mendon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuno Mendon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuno Mendon Today - Breaking & Trending Today

AC Immune Announces Upcoming Presentations at AD/PD™ 2024 - Vimarsana News

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its preci

Source: yahoo.com
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update - Vimarsana News

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

04.08.2023 - AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer’s disease (AD)Enrollment in ongoing Phase ...

AC Immune SA Appoints New Chief Medical Officer - AC Immune (NASDAQ:ACIU) - Vimarsana News

AC Immune SA Appoints New Chief Medical Officer - AC Immune (NASDAQ:ACIU)

AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage

BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson's Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene - Vimarsana News

BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson's Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

/PRNewswire/ -- BIAL - R&D Investments S.A (BIAL R&D), a subsidiary of BIAL Holding, S.A., today announced the dosing of the first patient in its Phase 2...

Charlyn Fargo Ware: Study Indicates More Protein Beneficial for Older Adults - Vimarsana News

Charlyn Fargo Ware: Study Indicates More Protein Beneficial for Older Adults

Noozhawk.com delivers local breaking news, local sports, schools, nonprofits, obituaries, business, arts and entertainment, calendar, local opinions and more.